Autologous Lymph Node Transfer with VEGF-C Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lymphedema, particularly secondary lymphedema resulting from surgery or radiation therapy, lack effective methods for preserving and integrating lymph nodes into the lymphatic network, leading to compromised skin flap survival and delayed wound healing in patients.
Innovation Solution
The method involves transferring or transplanting a lymph node or lymph node fragment and administering Vascular Endothelial Growth Factor C (VEGF-C) or VEGF-D polynucleotides/polypeptides to the perinodal site to promote lymph node survival and integration into the lymphatic network, enhancing lymphatic drainage and tissue healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radical axillary lymph node dissection is performed to eradicate breast cancer metastases, then cancer treatment efficacy is improved, but lymphatic drainage function deteriorates leading to lymphedema
Solution Approach 1:
The patent applies preliminary action by transplanting autologous lymph nodes to the axillary region before lymphedema fully develops, preventing the harmful effect while maintaining cancer treatment efficacy. The lymph nodes are prepared and positioned in advance to establish functional lymphatic drainage pathways prior to the onset of severe edema.
Solution Approach 2:
The transplanted autologous lymph nodes serve as an intermediary element that restores the disrupted lymphatic drainage system. These lymph nodes act as mediators between the surgical intervention and the lymphatic vessels, facilitating fluid transport and preventing lymphedema without compromising cancer eradication.
2Ease of operation
If conventional palliative care is provided for lymphedema patients, then patient comfort is maintained, but disease progression is not halted
Solution Approach 1:
The patent employs self-service by using the patient's own autologous lymph nodes for transplantation. The body's native lymph nodes are harvested and reimplanted to restore function, allowing the patient's own biological system to combat the disease rather than relying solely on external palliative measures.
Solution Approach 2:
The invention changes the fundamental parameter of lymphatic function by introducing functional lymph nodes through transplantation. This transforms the clinical state from progressive lymphedema to restored lymphatic drainage, shifting the disease trajectory without requiring complex external intervention systems.
3Reliability
If lymph node transplantation is performed to restore lymphatic drainage, then lymphedema treatment is improved, but skin flap survival and wound healing are compromised due to infection and ischemia
Solution Approach 1:
The patent utilizes readily available autologous lymph nodes that can be harvested during the same surgical procedure. These lymph nodes serve as temporary-to-permanent functional replacements that restore drainage capacity without requiring long-term external support systems, reducing the window of vulnerability to infection and ischemia.
4Reliability
If VEGF-C or VEGF-D therapy is administered to promote lymph node integration, then lymphatic network reconstitution is improved, but vascular permeability increases leading to edema
Solution Approach 1:
The patent applies local quality by administering VEGF-C or VEGF-D specifically to the transplanted lymph node region rather than systemically. This localized growth factor therapy promotes lymphatic endothelial cell proliferation and network integration at the target site while minimizing systemic vascular permeability changes that would cause generalized edema.
Solution Approach 2:
The continuous presence of VEGF-C or VEGF-D at the transplantation site sustains lymphatic vessel growth and maturation over time. This ongoing paracrine signaling ensures continuous integration of the transplanted lymph nodes into the host lymphatic network, establishing functional drainage pathways that persist long-term.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves lymph node survival and integration, reducing edema, and enhancing wound healing in patients with lymphedema, thereby addressing the challenges of skin flap survival and tissue healing post-surgical procedures.
Implementation Method 1
VEGF binds selectively and with high affinity to receptor tyrosine kinases VEGFR-1 and VEGFR-2. VEGF-C therapy has shown promising efficacy in preclinical animal models.
Implementation Method 2
VEGF is also known as vascular permeability factor, and it is more potent than histamine in increasing capillary permeability to plasma proteins.
Implementation Method 3
The lymphatic vasculature transports fluid and macromolecules from tissues back to the blood circulation
Data Source
AI summary
Materials and methods are provided to improve survival of lymph nodes and integration of lymph nodes into a lymphatic network, following lymph node transplantation. The treatment or prevention of lymphedema is also addressed. A method of lymph node transfer includes transferring or transplanting a lymph node or lymph node fragment in a mammalian subject; and administering a composition comprising an agent selected from the group consisting of Vascular Endothelial Growth Factor C (VEGF-C) polynucleotides, VEGF-C polypeptides, Vascular Endothelial Growth Factor D (VEGF-D) polynucleotides, and VEGF-D polypeptides to a perinodal site within 20 cm of the lymph node or lymph node fragment. In certain embodiments, the agent is present in the composition in an amount effective to promote survival of the lymph node and integration of the lymph node into a lymphatic network in the mammalian subject, at the site of transfer or transplantation.